Merck & Co., Inc. (MRK)
Merck scraps two late-stage trials of cancer drug Keytruda
Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial failures for the blockbuster drug.
Why Is Merck (MRK) Up 3.8% Since Last Earnings Report?
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate
Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood disorder.
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.
Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?
Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Merck (MRK) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Merck's Stock Dip Offers a Buying Opportunity: Here's Why
Global big pharmaceutical company Merck & Co. Inc. NYSE: MRK shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, but the lowered full-year EPS 2024 guidance sank the stock.
Buying Wonderful Businesses At Fair Prices - The Billionaire Way
Warren Buffett's success stems from evolving his strategy to focus on buying high-quality businesses at fair prices rather than just seeking deep-value investments. By deeply understanding businesses and investing with conviction, Buffett minimizes diversification and adopts an ownership mindset for long-term gains. Applying Buffett's principles, I explore three strong investment opportunities with solid growth potential, emphasizing quality, profitability, and attractive valuations.
Merck: Buy This Bargain Before It's Gone
Despite Merck beating analysts' expectations for the second quarter of 2024, its stock price fell 9%. The company's stock sell-off came as a result of an unexpected decline in sales of the Gardasil franchise in China and a cut in its forecast for full-year adjusted EPS. On the other hand, sales of Merck's oncology franchise totaled about $8.05 billion, up 16.4%, thanks to solid sales of Keytruda, its key blockbuster.
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
On Friday, Merck & Co Inc MRK agreed to acquire CN201, an investigational clinical-stage bispecific antibody for B-cell-associated diseases, from privately-held Curon Biopharmaceutical.
